Lantern Pharma Stock Analysis

Lantern Stock Analysis Notes

About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lantern Pharma recorded a loss per share of 1.78. The entity had not issued any dividends in recent years. Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Lantern Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Lantern Pharma contact Panna Sharma at 972 277 1136 or learn more at https://www.lanternpharma.com.

Lantern Pharma Investment Alerts

Lantern Pharma Upcoming and Recent Events

Lantern Largest EPS Surprises

View All Earnings Estimates

Lantern Pharma Environmental, Social, and Governance (ESG) Scores

Lantern Stock Institutional Investors

Note, although Lantern Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lantern Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.12 M.

Lantern Profitablity

Management Efficiency

Lantern Pharma has return on total asset (ROA) of (0.3394) % which means that it has lost $0.3394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5303) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to grow to -0.48. As of the 22nd of March 2025, Non Current Assets Total is likely to grow to about 363.2 K, while Total Assets are likely to drop about 36.4 M.

Technical Drivers

As of the 22nd of March, Lantern Pharma secures the Downside Deviation of 5.32, risk adjusted performance of 0.0404, and Mean Deviation of 4.55. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lantern Pharma, as well as the relationship between them.

Lantern Pharma Price Movement Analysis

Lantern Pharma Insider Trading Activities

Lantern Pharma Outstanding Bonds

Lantern Pharma Predictive Daily Indicators

Lantern Pharma Corporate Filings

Lantern Pharma Forecast Models

Lantern Pharma's time-series forecasting models are one of many Lantern Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lantern Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lantern Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lantern shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lantern Pharma. By using and applying Lantern Stock analysis, traders can create a robust methodology for identifying Lantern entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lantern analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lantern analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Lantern Pharma stock analysis indicators help investors evaluate how Lantern Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lantern Pharma shares will generate the highest return on investment. By understating and applying Lantern Pharma stock analysis, traders can identify Lantern Pharma position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.